12/16
04:01 pm
mrus
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
Medium
Report
Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC
12/10
12:27 pm
mrus
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy [Yahoo! Finance]
Neutral
Report
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy [Yahoo! Finance]
12/10
08:01 am
mrus
Merus (NASDAQ: MRUS) had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a "buy" rating on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its price target raised by analysts at Citigroup Inc. from $89.00 to $97.00. They now have a "buy" rating on the stock.
12/9
08:11 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
12/7
01:34 am
mrus
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC [Yahoo! Finance]
Medium
Report
Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC [Yahoo! Finance]
12/7
01:30 am
mrus
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
Medium
Report
Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC
12/6
03:24 pm
mrus
FDA Roundup: December 6, 2024 [Yahoo! Finance]
Low
Report
FDA Roundup: December 6, 2024 [Yahoo! Finance]
12/4
04:58 pm
mrus
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study [Yahoo! Finance]
Medium
Report
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study [Yahoo! Finance]
12/4
04:55 pm
mrus
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
Medium
Report
Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study
12/3
11:15 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $109.00 price target on the stock, down previously from $111.00.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $109.00 price target on the stock, down previously from $111.00.
12/2
08:07 am
mrus
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer [Yahoo! Finance]
Medium
Report
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer [Yahoo! Finance]
12/2
08:06 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
12/2
08:06 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
12/2
08:00 am
mrus
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
Low
Report
Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer
12/1
11:08 am
mrus
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 [Yahoo! Finance]
Medium
Report
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 [Yahoo! Finance]
12/1
11:05 am
mrus
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
Medium
Report
Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024
11/21
07:40 am
mrus
Merus (NASDAQ: MRUS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $73.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $73.00 price target on the stock.
11/20
08:06 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Medium
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
11/6
04:13 pm
mrus
Merus to Present at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Merus to Present at Upcoming Investor Conferences [Yahoo! Finance]
11/6
04:01 pm
mrus
Merus to Present at Upcoming Investor Conferences
Low
Report
Merus to Present at Upcoming Investor Conferences
11/5
06:30 am
mrus
Merus Receives FDA extension of PDUFA for zenocutuzumab
Low
Report
Merus Receives FDA extension of PDUFA for zenocutuzumab
11/1
08:15 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.
11/1
08:15 am
mrus
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $85.00 price target on the stock.
10/31
08:08 am
mrus
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
Low
Report
Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update
10/24
07:16 am
mrus
Merus (NASDAQ: MRUS) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $72.00 price target on the stock.
Low
Report
Merus (NASDAQ: MRUS) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $72.00 price target on the stock.